Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 30

CareDx Inc

CDNANASDAQ
Trade with Public
Trade with Public
$49.79
-2.57-4.91%
가까이에: Aug 28, 5:00 PM EST
$50.64
0.851.71%
시간외: Aug 28, 7:43 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

CareDx Financials

CareDx (CDNA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CareDx Q2 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $131.948M Beat $114.044M Estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.23 by 60.87 percent. This is a 270 percent increase over earnings of $0.10 per share from the same
Benzinga Newsdesk

PRO
CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est

CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $447.000 million-$465.000 million to $490.000 million-$500.000 million vs $455.924 million estimate.
Benzinga Newsdesk

PRO
CareDx Raises FY2026 Sales Guidance from $420.000M-$444.000M to $447.000M-$465.000M vs $436.665M Est

CareDx (NASDAQ:CDNA) raises FY2026 sales outlook from $420.000 million-$444.000 million to $447.000 million-$465.000 million vs $436.665 million estimate.
Benzinga Newsdesk

PRO
CareDx Q1 Adj. EPS $0.34 Beats $0.13 Estimate, Sales $117.700M Beat $104.034M Estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.13 by 161.54 percent. This is a 277.78 percent increase over earnings of $0.09 per share from the same
Benzinga Newsdesk

Earnings Scheduled For April 28, 2026

Benzinga Insights

CareDx Sharpens Focus On Core Testing Services

CareDx Inc. (CDNA) sells Lab Products business to EuroBio Scientific for $170 million in cash, focusing on higher-growth precision testing and digital solutions.
Vandana Singh

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved